Calcium AEP (2-aminoethylphosphoric acid)

Tier 3 — weak evidence · Cell membrane · Multiple sclerosis claims

A form of calcium promoted by one physician in the mid-20th century for multiple sclerosis and autoimmune conditions. Clinical evidence consists of uncontrolled case reports never replicated in RCTs. Mainstream neurology does not recognise it as an MS treatment. Generally safe at standard doses but unlikely to provide unique benefits.

Dose: 500–1,500 mg/day calcium AEP; no quality clinical evidence for MS or autoimmune claims